Compare GLOO & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLOO | VSTM |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 423.7M | 470.7M |
| IPO Year | 2025 | 2012 |
| Metric | GLOO | VSTM |
|---|---|---|
| Price | $5.32 | $5.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $13.75 | ★ $14.50 |
| AVG Volume (30 Days) | 54.0K | ★ 1.6M |
| Earning Date | 12-17-2025 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,523,000.00 | $13,379,000.00 |
| Revenue This Year | $429.89 | $208.54 |
| Revenue Next Year | $79.50 | $251.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 217.17 | 33.79 |
| 52 Week Low | $4.80 | $4.01 |
| 52 Week High | $9.98 | $11.25 |
| Indicator | GLOO | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 39.80 | 37.73 |
| Support Level | $5.08 | $6.26 |
| Resistance Level | $5.85 | $6.81 |
| Average True Range (ATR) | 0.57 | 0.41 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 31.90 | 8.33 |
Gloo Holdings Inc is engaged in building a technology platform company. It has provided a breadth of products, services, and solutions to the two primary stakeholders at the core of the faith and flourishing ecosystem: (1) network capability providers (NCPs) and (2) the churches and frontline organizations (CFLs) it serves. The company serves as a digital infrastructure between NCPs and CFLs. By facilitating efficient exchange between the two, Gloo enables both sides to succeed; CFLs gain access to resources and NCPs benefit from efficient distribution and targeted reach. This creates a virtuous cycle, strengthening the platform with each interaction. The Gloo platform includes a suite of technology, marketplace, and service solutions offered directly from Gloo or from Gloo's subsidiaries.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.